pipette
ESEspañol

Screening Renin-Aldosterone Profiles and Long-term Cardiovascular Risk After Primary Aldosteronism Evaluation

H.-C. Pan, K.-H. Chen, C.-H. Tsai, Y.-H. Lin, C.-Y. Wang, V.-C. Wu

PreprintReal-world use

In the authors' words

Background: Aldosterone-to-renin ratio (ARR) and plasma renin activity (PRA) are measured at the screening stage of primary aldosteronism (PA) evaluation, but their prognostic relevance after confirmatory classification and subsequent treatment remains uncertain. Methods: We linked the seven-hospital Taiwan Primary Aldosteronism Investigation cohort (1991-2023) with nationwide health insurance and mortality data through June 2025. Patients were classified as confirmatory-test-defined essential hypertension (EH), PA without adrenalectomy, or PA with subsequent adrenalectomy. Covariate-adjusted Cox models evaluated screening logARR, logPRA, and logPAC separately in relation to incident major adverse cardiovascular events (MACE; myocardial infarction, stroke, heart failure hospitalization, or cardiovascular death). Results: Among 3,178 participants (EH, 1,433; PA without adrenalectomy, 834; PA with adrenalectomy, 911), 441 (13.9%) experienced MACE during a median 7.9-year follow-up. Adjusted hazard ratios (95% CIs) per 1-unit increase in logARR were 1.09 (1.00-1.19), 1.14 (1.03-1.26), and 0.95 (0.87-1.05), respectively; corresponding logPRA estimates were 0.91 (0.83-0.99), 0.87 (0.79-0.97), and 1.04 (0.93-1.16). LogPAC showed no consistent associations. Primary biomarker-by-phenotype interactions were not significant for logARR (P=0.057) or logPRA (P=0.069); time-varying adrenalectomy analyses were supportive but exploratory. Conclusions: Higher screening ARR and lower PRA were associated with subsequent MACE in confirmatory-test-defined EH and PA without adrenalectomy, but not clearly in PA with subsequent adrenalectomy.

Main resultLimitation the authors admit

Appeared: Wednesday, November 11. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.09.26367682